Product Information
ETHOSUXIMIDE 250 MG/5 ML SOLN is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.0939 per ML under NDC 59762235007. Its NADAC has been published 207 times since Sep 7, 2022.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AA.
The Low Outlier badge above means this manufacturer's average price in the Ethosuximide market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
250 mg/5mL
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762235007
Classification
Generic
Dosage Form
SOLUTION
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
ETHOSUXIMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA080258FDA Approved
Before 1982
TE Code
AA
On Market Since
2/21/2020
Pharmacological Classes
Price Statistics
The NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has been published 207 times since Sep 7, 2022, and over the history we have for it it has risen 28.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0939 per ML |
|---|---|
| All-time high | $0.0965 (Oct 15, 2025) |
| All-time low | $0.0631 (Apr 17, 2024) |
| 52-week high | $0.0965 |
| 52-week low | $0.0879 |
| Median price | $0.0863 |
| Average price | $0.0853 |
| Largest weekly change | +35.0% (Feb 26, 2025) |
| Weeks tracked | 207 |
| Tracking since | Sep 7, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 17% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ETHOSUXIMIDE 250 MG/5 ML SOLN?
The current National Average Drug Acquisition Cost (NADAC) for ETHOSUXIMIDE 250 MG/5 ML SOLN, manufactured by Mylan Pharmaceuticals Inc., is $0.0939 per ML (NDC 59762235007), effective Aug 19, 2026.
How has the price of ETHOSUXIMIDE 250 MG/5 ML SOLN changed over time?
Over the history we have for it, the NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has risen 28.0%. It has been tracked across 207 weekly CMS publications since Sep 7, 2022.
What are the highest and lowest recorded NADAC prices for ETHOSUXIMIDE 250 MG/5 ML SOLN?
Since Sep 7, 2022, the NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has ranged from a low of $0.0631 (Apr 17, 2024) to a high of $0.0965 (Oct 15, 2025), with a median of $0.0863 per ML.
Are there cheaper alternatives to ETHOSUXIMIDE 250 MG/5 ML SOLN?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ETHOSUXIMIDE 250 MG/5 ML SOLN, is $0.0780 per ML — about 17% below ETHOSUXIMIDE 250 MG/5 ML SOLN.
Who manufactures ETHOSUXIMIDE 250 MG/5 ML SOLN?
ETHOSUXIMIDE 250 MG/5 ML SOLN (NDC 59762235007) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.